Roy S. Herbst, MD, PhD
机构: Yale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New Haven
每年引用次数
引用次数
引用: 105,712
H-指数: 146
I10-指数 : 487
出版物: 998
IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).
Jacek Jassem , Roy S. Herbst , Filippo de Marinis , Jacques Cadranel
Journal of Clinical Oncology 38 ( 15_suppl) e21623 -e21623
1
2020
A multi-stakeholder platform to prospectively link longitudinal real-world clinico-genomic, imaging, and outcomes data for patients with metastatic lung cancer.
Michael W Lu , Guneet Walia , Katja Schulze , Michelle Yuri Doral
Journal of Clinical Oncology 38 ( 15_suppl) TPS2087 -TPS2087
2020
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Roy S. Herbst , Masahiro Tsuboi , Thomas John , Christian Grohé
Journal of Clinical Oncology 38
37
2020
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Scott Gettinger , Jungmin Choi , Katherine Hastings , Anna Truini
Cancer Discovery 7 ( 12) 1420 -1435
226
2017
Frontline immunotherapy for NSCLC - the tale of the tail
Anne C. Chiang , Roy S. Herbst
Nature Reviews Clinical Oncology 17 ( 2) 73 -74
16
2020
Larotrectinib in NTRK-Rearranged Solid Tumors Published as part of the Biochemistry series "Biochemistry to Bedside"
Frederick H. Wilson , Roy S. Herbst
Biochemistry 58 ( 12) 1555 -1557
2
2019
Bevacizumab and Erlotinib: A Promising New Approach to the Treatment of Advanced NSCLC
Roy S. Herbst , Alan Sandler
Oncologist 13 ( 11) 1166 -1176
45
2008
Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop
Erin P. Balogh , Carolyn Dresler , Mark E. Fleury , Ellen R. Gritz
Oncologist 19 ( 1) 21 -31
16
2014
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
Hendrik‐Tobias Arkenau , Juan Martin‐Liberal , Emiliano Calvo , Nicolas Penel
Oncologist 23 ( 12) 1407
127
2018
Tobacco and cancer: An American Association for Cancer Research policy statement
Kasisomayajula Viswanath , Roy S. Herbst , Stephanie R. Land , Scott J. Leischow
Cancer Research 70 ( 9) 3419 -3430
64
2010
Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy
Fei Yang , Ximing Tang , Erick Riquelme , Carmen Behrens
Cancer Research 71 ( 16) 5512 -5521
44
2011
To kill a tumor cell: the potential of proapoptotic receptor agonists
Avi Ashkenazi , Roy S. Herbst
Journal of Clinical Investigation 118 ( 6) 1979 -1990
275
2008
P-484 Synchronous overexpression of epidermal growth factor receptor and HER2-NEU is a predictor of poor outcome in patients with stage I non-small cell lung cancer
Amir Onn , Arlene M. Correa , Michael Gilcrease , Erminia Massarelli
Lung Cancer 41
10
2003
Lung cancer in patients under age 40.
Arthur T. Skarin , Roy S. Herbst , Traci L. Leong , Allison Bailey
Lung Cancer 32 ( 3) 255 -264
158
2001
Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results
Ralph G. Zinner , Jeri Kim , Roy S. Herbst
Lung Cancer 37 ( 1) 17 -27
27
2002
I-95. Targeting the EGFR: Prognostic and clinical implications
Roy S. Herbst
Lung Cancer 41 S114
2003
O-290 Blockade of EGFR tyrosine kinase does not predict outcome in a new orthotopic model of human lung cancer
Amir Onn , Takeshi Isobe , Satoshi Itasaka , Wenjuan Wu
Lung Cancer 41
2003
O-311 A phase III study of Æ-941 (Neovastat®) with induction chemotherapy (IC) and conconmitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim analysis of toxicity and response
Charles Lu , Ritsuko Komaki , Roy S. Herbst , William K. Evans
Lung Cancer 41
2003
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition
Seung-Hyun Oh , Ok-Hee Lee , Claudia P. Schroeder , Yun W. Oh
Molecular Cancer Therapeutics 5 ( 11) 2685 -2695
36
2006
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade
Wenjuan Wu , Amir Onn , Takeshi Isobe , Satoshi Itasaka
Molecular Cancer Therapeutics 6 ( 2) 471 -483
75
2007